Rusfertide Meets Primary Endpoint in Clinical Trial for PV patients

Protagonist Therapeutics, Inc., announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE, a study evaluating rusfertide, a subcutaneous injectable hepcidin mimetic, in patients with polycythemia vera (PV).

Want to read more?

Subscribe to gmpnsf.org to keep reading this exclusive post.

Subscribe Now